PCAS SUSTAINED GROWTH IN NET SALES
Longjumeau, July 19, 2017
PCAS (Euronext Paris: PCA), a specialist in developing and producing complex molecules for life sciences and innovative technologies, has announced the publication of its consolidated net sales for the first half of 2017.
The PCAS Group had generated consolidated net sales of €110.2 million in the first half of 2017, representing growth of +9.4% compared to the same period during the previous financial year (+9.1% at a constant exchange rate).
Pharmaceutical Synthesis
The Pharmaceutical Synthesis business generated €75.8 million, up +10.5% on 2016 (+10.5% at a constant exchange rate), which was especially driven by the Exclusive activity.
Fine Specialty Chemicals
Net sales of Fine Specialty Chemicals totaled €34.4 million, up 7.1% on 2016 (+6.2% at a constant exchange rate), with growth in both Performance Additives and Advanced Specialty Chemicals for micro-electronic chemicals.
Outlook for the current year
The company has confirmed its growth targets for net sales in 2017 and for all its lines of business.
| NEXT FINANCIAL DISCLOSURE: | |
| First half 2017 earnings report, September 6, 2017 |
ABOUT PCAS
PCAS specializes in the development and production of complex molecules for life sciences and innovative technologies. With 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. Boasting especially high standards, the company offers a growing range of proprietary products and solutions in leading-edge segments. PCAS generated net sales of €192.0 million in 2016 and employs close to 1000 people in six countries.
To find out more about PCAS, visit: www.pcas.com
| PCAS | NewCap |
| Vincent Touraille / Eric Moissenot PCAS | Emmanuel Huynh / Louis-Victor Delouvrier NewCap Financial communication and Investor Relations |
| Tel. : +33 1 69 79 61 32 www.pcas.com | Tel. : +33 1 44 71 98 53 pcas@newcap.eu |
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: PCAS via Globenewswire
